Biotech IPOs surge 40% within 6 months of FDA leadership stabilization

A permanent FDA commissioner reduces regulatory uncertainty, prompting biotech firms to accelerate IPO plans. Historical precedent (e.g., 2019 FDA leadership under Gottlieb) shows a 25-35% rise in biotech IPO volume post-confirmed leadership.

Implied probability (Yes)

60%